NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: CORONA · data 2026-10-30
Corona Remedies Limited
In plain words
Price: 6.2% below its 52-week high of ₹2,292.4.
Delivery: 55.7% of traded shares were kept for delivery over the last 10 sessions, against 52.3% over the last 60.
Latest results: a net profit of ₹60 cr for the quarter ended Sept 2026 (+15.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,479 cr |
| Net profit (last 12 months) | ₹199 cr |
| Sales growth, 3 years (yearly) | 16.6% |
| Profit growth, 3 years (yearly) | 29.7% |
Latest results in brief (Q2 FY27)
CORONA Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹441.17 crore, up 22.2% YoY and up 4.4% QoQ.
Net profit was ₹60.31 crore, up 15.3% YoY and up 0.3% QoQ.
Operating margin was 21.7% (21.7% a year ago).
EPS was ₹9.86, up 15.3% YoY and up 0.3% QoQ.
CORONA के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹441.17 करोड़; पिछले साल की तुलना में 22.2% की बढ़त, पिछली तिमाही की तुलना में 4.4% की बढ़त।
शुद्ध मुनाफ़ा: ₹60.31 करोड़; पिछले साल की तुलना में 15.3% की बढ़त, पिछली तिमाही की तुलना में 0.3% की बढ़त।
ऑपरेटिंग मार्जिन: 21.7% (एक साल पहले 21.7%)।
EPS: ₹9.86; पिछले साल की तुलना में 15.3% की बढ़त, पिछली तिमाही की तुलना में 0.3% की बढ़त।
CORONAના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹441.17 કરોડ; ગયા વર્ષની સરખામણીએ 22.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4.4% વધારો.
ચોખ્ખો નફો: ₹60.31 કરોડ; ગયા વર્ષની સરખામણીએ 15.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 0.3% વધારો.
ઓપરેટિંગ માર્જિન: 21.7% (એક વર્ષ પહેલાં 21.7%).
EPS: ₹9.86; ગયા વર્ષની સરખામણીએ 15.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 0.3% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
41/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 57.0% over the last 20 sessions vs 43.8% in the 40 before (1.3x); shares delivered per day 0.77x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 11 schemes hold it, about ₹577 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 70/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 30 Oct 26Results Q2 FY27 results: profit +15.3% YoY
- 31 Jul 26Results Q1 FY27 results: net profit ₹60.1 cr +0.7% next session
- 19 Jun 26Dividend Dividend ₹10 (ex-date) +0.6% next session
- 11 May 26Results Q4 FY26 results: net profit ₹45.3 cr -4.7% next session
- 2 Feb 26Results Q3 FY26 results: net profit ₹41.3 cr +3.7% next session
- 5 Jan 26Results Q2 FY26 results: net profit ₹52.3 cr -0.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹441 cr | ₹60 cr | +15.3% | 21.7% | 9.86 |
| Jun 2026 | ₹422 cr | ₹60 cr | — | 22.0% | 9.83 |
| Mar 2026 | ₹353 cr | ₹45 cr | — | 17.6% | 7.41 |
| Dec 2025 | ₹342 cr | ₹41 cr | — | 24.3% | 6.75 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 69.00% | 69.00% | 69.00% | 69.00% |
| Foreign institutions (FII) | 4.21% | 3.63% | 2.25% | 1.84% |
| Domestic institutions (DII) | 16.45% | 12.90% | 7.02% | 6.76% |
| Mutual funds | 16.06% | 12.50% | 6.35% | 6.38% |
| Retail investors | 1.03% | 0.85% | 0.69% | 1.14% |
| Number of shareholders | 21,098 | 20,185 | 19,609 | 31,035 |
Common questions
What was Corona Remedies Limited's latest quarterly profit?
Corona Remedies Limited reported a net profit of ₹60 cr for the quarter ended Sept 2026 (+15.3% on the same quarter a year earlier), on revenue of ₹441 cr.
How much do promoters hold in Corona Remedies Limited?
Promoters held 69.00% of Corona Remedies Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Corona Remedies Limited debt-free?
Its latest reported debt-to-equity ratio is 0.22.
What is Corona Remedies Limited's P/E ratio?
About 66.1, based on the last 12 months' earnings and a price of ₹2,149.6 (data 2026-10-30).
What is the 52-week high and low of Corona Remedies Limited?
The 52-week high is ₹2,292.4 and the 52-week low is ₹1,336.6.
Mutual funds holding Corona Remedies Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 11 schemes holding about ₹577 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Dividend Yield Fund | SBI Mutual Fund | 2.23% | ₹180 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.43% | ₹143 cr |
| ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND | Aditya Birla Sun Life Mutual Fund | 0.71% | ₹96 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN | SBI Mutual Fund | 2.07% | ₹64 cr |
| SBI Balanced Hybrid Fund | SBI Mutual Fund | 1.59% | ₹32 cr |
| SBI RETIREMENT BENEFIT FUND - AGGRESSIVE HYBRID PLAN | SBI Mutual Fund | 1.65% | ₹26 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 2.27% | ₹25 cr |
| SBI Long Term Advantage Fund - Series VI | SBI Mutual Fund | 2.11% | ₹5 cr |
| SBI Long Term Advantage Fund - Series V | SBI Mutual Fund | 1.43% | ₹5 cr |
| SBI RETIREMENT BENEFIT FUND - CONSERVATIVE HYBRID PLAN | SBI Mutual Fund | 0.81% | ₹2 cr |
| SBI RETIREMENT BENEFIT FUND - CONSERVATIVE PLAN | SBI Mutual Fund | 0.41% | ₹1 cr |
Similar companies
NATCO Pharma Limited (NATCOPHARM) · Jubilant Pharmova Limited (JUBLPHARMA) · Indegene Limited (INDGN) · Marksans Pharma Limited (MARKSANS) · Anupam Rasayan India Ltd. (ANURAS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CORONA in NSE Scanner →